Radius falters after a PhIII osteoporosis fail and a breast cancer disappointment, sending shares plummeting
Radius Health saw shares tank on Wednesday after reporting two Phase III study results, one for an osteoporosis patch treatment that failed and one for a breast cancer therapy showing lower efficacy results than expected.
The biotech is looking to develop a patch version of its injectable Tymlos drug for osteoporosis in postmenopausal women, but the treatment missed its primary endpoint and did not show non-inferiority relative to the approved injection. Radius is still angling to develop the treatment, but execs said in an investor call it would cause at least a two-year delay.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.